Which antifungal agents are potent CYP3A4 inhibitors and can interact with statins and cause QT prolongation?

• A. Azoles such as ketoconazole, itraconazole, voriconazole; caution with statins due to myopathy risk; monitor QT.
• B. Echinocandins such as caspofungin; no QT effect.
• C. Amphotericin B; interacts with statins strongly.
• D. Terbinafine; with no cardiac effects.

Answer: (A)

Potent inhibition of CYP3A4 by certain antifungals can create clinically important drug interactions with statins and may affect cardiac repolarization. The azole class—ketoconazole, itraconazole, and voriconazole—are strong CYP3A4 inhibitors. Because many statins (notably simvastatin, atorvastatin, and lovastatin) are metabolized by CYP3A4, these antifungals can substantially raise statin levels, increasing the risk of muscle toxicity or rhabdomyolysis. In addition, voriconazole and some other azoles can prolong the QT interval by affecting cardiac repolarization, which raises the risk of torsades de pointes, especially with other QT-prolonging drugs or electrolyte disturbances.

Other antifungal classes do not share this combination of strong CYP3A4 inhibition and QT prolongation risk: echinocandins have minimal CYP interactions and little to no QT effect, amphotericin B has a different toxicity and interaction profile, and terbinafine is not a potent CYP3A4 inhibitor with the same QT concerns. Therefore, the azole antifungals are the ones that fit the described interaction pattern.